Mechanisms of abnormal renal sodium handling in obesity hypertension - PubMed (original) (raw)
Review
. 1997 May;10(5 Pt 2):49S-55S.
Affiliations
- PMID: 9160781
Review
Mechanisms of abnormal renal sodium handling in obesity hypertension
J E Hall. Am J Hypertens. 1997 May.
Abstract
Obesity-induced hypertension, like all forms of experimental and human hypertension studied thus far, is associated with renal dysfunction characterized by the resetting of pressure natriuresis. In obese subjects, this resetting is primarily a result of increased renal tubular reabsorption as glomerular filtration rate and renal blood flow are markedly elevated. Obesity activates the sympathetic nervous and renin-angiotensin systems, and causes insulin resistance and hyperinsulinemia, all of which have been postulated to increase tubular reabsorption and raise blood pressure. In humans and dogs, chronic hyperinsulinemia, comparable to that found in obesity, does not cause hypertension even in the presence of insulin resistance. Activation of the sympathetic nervous system appears to be important in obesity, as chronic adrenergic blockade or renal denervation greatly ameliorates the hypertension associated with weight gain. Resetting of pressure natriuresis in obesity may also be attributable to altered intrarenal forces caused by histologic changes in the renal medulla that may compress the loops of Henle and vasa recta, increase tubular sodium reabsorption, and activate the renin-angiotensin system. The quantitative importance of these intrarenal changes and their interrelationship with neurohumoral activation in obesity is an important area for further investigation.
Similar articles
- Obesity hypertension, salt sensitivity and insulin resistance.
Rocchini AP. Rocchini AP. Nutr Metab Cardiovasc Dis. 2000 Oct;10(5):287-94. Nutr Metab Cardiovasc Dis. 2000. PMID: 11213538 Review. - Mechanisms of obesity-induced hypertension.
Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Kotsis V, et al. Hypertens Res. 2010 May;33(5):386-93. doi: 10.1038/hr.2010.9. Hypertens Res. 2010. PMID: 20442753 Review. - Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity.
Hall JE. Hall JE. Hypertension. 1994 Mar;23(3):381-94. doi: 10.1161/01.hyp.23.3.381. Hypertension. 1994. PMID: 8125566 Review. - Renal consequences of obesity.
Naumnik B, Myśliwiec M. Naumnik B, et al. Med Sci Monit. 2010 Aug;16(8):RA163-70. Med Sci Monit. 2010. PMID: 20671624 Review. - Hyperinsulinemia, insulin resistance, and hypertension.
Bönner G. Bönner G. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S39-49. J Cardiovasc Pharmacol. 1994. PMID: 7898093 Review.
Cited by
- Hypopnea in pediatric patients with obesity hypertension.
Reade EP, Whaley C, Lin JJ, McKenney DW, Lee D, Perkin R. Reade EP, et al. Pediatr Nephrol. 2004 Sep;19(9):1014-20. doi: 10.1007/s00467-004-1513-1. Epub 2004 Jun 4. Pediatr Nephrol. 2004. PMID: 15179571 - Kidney and epigenetic mechanisms of salt-sensitive hypertension.
Kawarazaki W, Fujita T. Kawarazaki W, et al. Nat Rev Nephrol. 2021 May;17(5):350-363. doi: 10.1038/s41581-021-00399-2. Epub 2021 Feb 24. Nat Rev Nephrol. 2021. PMID: 33627838 Review. - Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management.
Gupta H, Bhandari U. Gupta H, et al. Curr Drug Targets. 2025;26(3):188-202. doi: 10.2174/0113894501314788241008115712. Curr Drug Targets. 2025. PMID: 39411934 Review. - A Review on In-vivo and In-vitro Models of Obesity and Obesity-Associated Co-Morbidities.
Nath D, Barbhuiya PA, Sen S, Pathak MP. Nath D, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(6):458-478. doi: 10.2174/0118715303312932240801073903. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39136512 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical